EMA’s New Amsterdam HQ to be Ready by November 2019
Posted 28 February 2018 | By
The European Medicines Agency’s (EMA) Management Board met on Wednesday in what it calls an extraordinary session, voting to endorse the revised offer of the Dutch government regarding the agency’s new permanent premises in Amsterdam’s business district, Zuidas.
Dutch authorities committed to building the tailor-made premises and confirmed to the board that the permanent building will be ready by 15 November 2019.
“The decision taken by the Board today is an important milestone for EMA and the Netherlands. The notification to the EU’s Budgetary Authority of EMA’s intention to move to a new headquarters is required by the Agency’s financial regulation and is a key step in the building approval process,” EMA said in a statement
. “EMA can only enter into a contractual obligation for its new final premises following a positive opinion from these bodies. Upon the Agency’s notification, the Budgetary Authority is expected to provide an opinion within four weeks.”
The board’s extraordinary meeting took place in the margins of the Heads of Medicines Agencies meeting, which is taking place in Lisbon, Portugal from 28 February to 2 March.
In related Brexit news, Article 41 of the European Commission’s draft withdrawal agreement
with the UK says that the UK should be ready to make available information on past authorization procedures for medicinal products.